Merus Management
Management criteria checks 4/4
Merus' CEO is Bill Lundberg, appointed in Dec 2019, has a tenure of 5.5 years. total yearly compensation is $4.67M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $6.36M. The average tenure of the management team and the board of directors is 2.9 years and 6.3 years respectively.
Key information
Bill Lundberg
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 13.9% |
| CEO tenure | 5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 05We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$245m |
| Jun 30 2024 | n/a | n/a | -US$168m |
| Mar 31 2024 | n/a | n/a | -US$150m |
| Dec 31 2023 | US$5m | US$650k | -US$155m |
| Sep 30 2023 | n/a | n/a | -US$177m |
| Jun 30 2023 | n/a | n/a | -US$178m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$6m | US$599k | -US$131m |
| Sep 30 2022 | n/a | n/a | -US$64m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$8m | US$582k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$5m | US$565k | -US$86m |
| Sep 30 2020 | n/a | n/a | -US$83m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$65m |
| Dec 31 2019 | US$162k | n/a | -US$55m |
Compensation vs Market: Bill's total compensation ($USD4.67M) is about average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
CEO
Bill Lundberg (61 yo)
5yrs
Tenure
US$4,671,327
Compensation
Dr. Sven Ante Lundberg, also known as Bill, M.D. is Venture Advisor of Forge Life Science Partners. He serves as Chief Executive Officer, President and Executive Director of Merus N.V. since December 31, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 5yrs | US$4.67m | 0.22% $ 6.4m | |
| Chief Financial Officer | 1.5yrs | US$6.21m | 0% $ 0 | |
| EVP, Company Secretary | 6.8yrs | US$1.95m | no data | |
| Co-Founder and Scientific Advisor | no data | no data | no data | |
| Chief Accounting Officer | no data | no data | 0.010% $ 293.1k | |
| CTO & Executive VP | 11.9yrs | US$609.22k | no data | |
| Chief Scientific Officer & Senior VP | 3.6yrs | no data | no data | |
| IR & Corporate Communications Officer | no data | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Executive VP & Chief Commercial Officer | 2.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.9yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
59yo
Average Age
Experienced Management: MRUS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 5.5yrs | US$4.67m | 0.22% $ 6.4m | |
| Board Observer | 14.9yrs | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | US$305.06k | 0% $ 0 | |
| Independent Chairman | 9.3yrs | US$417.56k | 0% $ 0 | |
| Independent Non-Executive Director | 4.5yrs | US$309.56k | 0% $ 0 | |
| Independent Non Executive Director | 9.5yrs | US$311.06k | 0.11% $ 3.1m | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Non-Executive Director | 5.5yrs | US$303.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 6.4yrs | US$303.56k | 0% $ 0 |
6.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: MRUS's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Merus N.V. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |